[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Contempo Updates
May 9, 2001

Clinical Xenotransplantation

Author Affiliations

Author Affiliations: HIV/AIDS and Retrovirology Branch, Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Ga (Dr Chapman); Laboratory of Immunology and Virology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Md (Dr Bloom).

 

Contempo Updates Section Editor: Alice T. D. Hughes, MD, Fishbein Fellow.

JAMA. 2001;285(18):2304-2306. doi:10.1001/jama.285.18.2304

The remarkable half-century transition of whole organ transplantation from experimental intervention to standard clinical practice has resulted in a growing disparity between the number of persons who could potentially benefit from allotransplants and the availability of transplantable human organs.1 This disparity inspired initial attempts to explore alternative therapies for organ failure, among them xenotransplantation, which involves the use of living, nonhuman animal tissues in humans.

First Page Preview View Large
First page PDF preview
First page PDF preview
×